Sign In
Buy ADIL
$2.71
+0.110 (+4.23%)
At Close: Jun 22, 2026
Adial Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
09:00am, Wednesday, 04'th Sep 2024
GLEN ALLEN, Va., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing ther
Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
08:30am, Wednesday, 14'th Aug 2024
GLEN ALLEN, Va., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing thera
Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
09:00am, Wednesday, 07'th Aug 2024
Patient dosing has concluded for the second and last cohort of the pharmacokinetics study of AD04 Topline results expected during the fourth quarter GLEN ALLEN, Va., Aug. 07, 2024 (GLOBE NEWSWIRE) --
Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044
08:30am, Wednesday, 31'st Jul 2024
Expected New Patent Based on Extensive Review of Data and Information Expected New Patent Based on Extensive Review of Data and Information
Why Is Adial Pharmaceuticals (ADIL) Up 61% Today?
12:00pm, Tuesday, 23'rd Jul 2024
Adial Pharmaceuticals (NASDAQ:ADIL) stock is rocketing higher on Tuesday after the clinical-stage biopharmaceutical company announced an update on its AD04 study. Adial Pharmaceuticals notes that AD04
Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
08:30am, Tuesday, 23'rd Jul 2024
Patient dosing in the second cohort has commenced following the successful completion of the first cohort Patient dosing in the second cohort has commenced following the successful completion of the f
AD04 reduced heavy drinking days among heavy drinking individuals with alcohol use disorder and a specific genetic profile, as identified by a companion diagnostic test (CDx) AD04 reduced heavy drinki
Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025
03:17pm, Wednesday, 05'th Jun 2024
Making millions through the stock market is only possible in a few ways. Investors need one of these three things: Massive sums of capital to begin with Decades of time and more modest sums of capital
Adial CEO to Present at the Spring MicroCap Rodeo Conference on June 6th
08:30am, Wednesday, 29'th May 2024
GLEN ALLEN, Va., May 29, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therap
Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
08:30am, Wednesday, 15'th May 2024
GLEN ALLEN, Va., May 15, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therap
Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office
08:30am, Monday, 22'nd Apr 2024
GLEN ALLEN, Va., April 22, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing ther
Adial Pharmaceuticals posts promising update on alcohol disorder drug
02:15pm, Wednesday, 10'th Apr 2024
Adial Pharmaceuticals Inc (NASDAQ: ADIL) is up 60% today following a promising update on its alcohol disorder drug. What it means for Adial Pharmaceuticals stock The $7.7 million company based out of
Why Is Adial Pharmaceuticals (ADIL) Stock Up 59% Today?
11:53am, Wednesday, 10'th Apr 2024
Adial Pharmaceuticals (NASDAQ: ADIL ) stock is heading higher on Wednesday following positive results from a peer review of its Alcohol Use Disorder ( AUD ) treatment. This peer review focuses on Phas
Findings underscore the liver safety of AD04 as compared to placebo in the prior Phase 3 clinical trial Findings underscore the liver safety of AD04 as compared to placebo in the prior Phase 3 clinica
Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update
08:30am, Tuesday, 02'nd Apr 2024
Received Favorable Feedback from US and EU Regulatory Agencies Advancing Discussions with Potential Strategic Partners Received $4.3 Million in Gross Proceeds from Warrant Exercises Subsequent to Year
